Carisma Therapeutics Inc.

CARM | OTC | CIK: 0001485003 | SIC: 2834 Pharmaceutical Preparations | active
Carisma Therapeutics Inc. is a biotechnology company focused on macrophage and monocyte engineering to develop therapies for liver fibrosis and cancer. Its proprietary CAR-M platform uses chimeric antigen receptors to redirect macrophages against tumor-associated antigens. Key candidates include CT-2401 (liver fibrosis, mRNA/LNP approach) and CT-1119 (mesothelin-positive solid tumors). Following strategic reviews in 2024-2025, the company paused R&D and is exploring strategic alternatives including asset sales, partnerships, or a company merger.
liver-fibrosis-treatmentoncology-/-solid-tumor-cancer-therapycell-and-gene-therapymyeloid-cell-immunotherapychimeric-antigen-receptor-(car)-technologymrna/lipid-nanoparticle-(lnp)-deliveryex-vivo-cell-engineeringin-vivo-macrophage-engineering
AI agents: Get this data as structured JSON (~200 tokens):
https://origin.rootz.global/api/company/CARM
Profile | Timeline | SEC Filings | People

Products

NameTypeDescription
CT-2401platformmRNA/LNP-based product candidate targeting liver fibrosis via engineered macrophages; achieved pre-clinical proof of concept in Q2 2024.
CT-1119platformMesothelin-targeted CAR-Monocyte product candidate for advanced solid tumors including pancreatic, ovarian, and lung cancer; development paused.
CT-0525platformHER2-directed CAR-Monocyte autologous cell therapy for solid tumors; development ceased in December 2024 after Phase 1 trial.
CT-0508platformMacrophage-based initial lead product candidate; all clinical activities ceased as of the 2024 revised operating plan.
CAR-M PlatformplatformProprietary chimeric antigen receptor macrophage platform for redirecting macrophages and monocytes against tumor-associated antigens.

Partnerships

PartnerTypeDescription
ModernaTX, Inc.developmentCollaboration on in vivo mRNA/LNP CAR-M programs; Carisma eligible to receive future milestones and royalty payments.

SEC Filings

View all SEC EDGAR filings: EDGAR Company Page

Structured filing index: /api/company/CARM/filings

Origin — Data Provenance
This profile was extracted from SEC EDGAR filings (PEM-signed by sec.gov).
Every API response includes a cryptographic origin leaf for chain-of-custody tracking.
AI Discovery Document | Registry Metrics | GitHub